Immunotech Laboratories Appoints New VP of Business Development
4/15/2013 9:28:57 AM
MONROVIA, CA--(Marketwired - April 15, 2013) - Immunotech Laboratories, Inc. (PINKSHEETS: IMMB) announces the company has appointed Blaine Nabors as VP of Business Development.
Immunotech President & Founder Harry Zhabilov today announced the appointment of Blaine Nabors as Immunotech's VP of Business Development.
Commencing April 08, 2013, Blaine Nabors reached an agreement with Immunotech for the position VP of Business Development.
The position includes day-to-day operations along with assistance for the business marketing strategy and development along with brand marketing recognition. Additional duties will include assistance and communication for the FDA Strategy & Interaction, Regulatory Planning & Execution, Product Development and its Commercialization.
Active involvement in development of a marketing strategy for prospective clients along with continued maintenance of public relations while reviewing, updating and guidance in creating a marketing plan that will generate relationships with Bio-medical companies within the same sector.
Mr. Nabors stated, "I'm very pleased to accept this position offered by Immunotech laboratories. This is such an amazing creation that can save millions of lives around the world. I'm honored to be a part of such a revolutionary proprietary treatment of debilitating infectious diseases. As we move forward to bringing this recognition to the general public through the FDA process, I look forward to what lies ahead for Immunotech laboratories and its further development for all. "
About Immunotech Laboratories
Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases such as HIV and Aids. www.immunotechlab.com
Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.
The Nabors Group
E-mail: Email Contact